BioSpace News Archive

Neon Therapeutics filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO) and hopes to raise $115 million.

The ink is barely dry on the recently-passed “Right to Try Act,” and the law’s author, Sen. Ron Johnson (R-Wis.) and U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb are butting heads.

FDA Commissioner Scott Gottlieb released a statement on new policies aimed to combat the practice of using certain agency requirements to block timely generic drug entry.

Amgen, and The University of Texas MD Anderson Cancer Center, announced two multi-year collaborative research deals for a broad range of cancer therapeutics.

AbbVie announced findings from an interim analysis of the Phase 3 iNNOVATE (PCYC-1127) study evaluating IMBRUVICA® (ibrutinib) plus RITUXAN® (rituximab).

Additional one-year follow-up study results show low incidence of cardiac safety events and no statistically significant difference in survival results compared to reference trastuzumab in the SB3 treatment group

Collaboration between Sarah Cannon Research Institute and the Sidney Kimmel Cancer Center – Jefferson Health to Enhance Clinical Trial Offerings & Expand Phase 1 Research Capabilities.

Boston Scientific announced key data that will be presented at Digestive Disease Week (DDW).

Co-Diagnostics, Inc. (NASDAQ: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today that the Company’s CoPrimer™ technology is being employed to achieve the objectives of a research project conducted by the Wang Group at Stanford University.

For the 12 months ended April 2018, total U.S. sales of Levofloxacin Oral Solution USP, 25 mg/mL, was approximately $6 million, according to IMS.